Ivosidenib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 379 publications

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

MechAInistic: An LLM-guided Multi-Agent System for Reasoning over Genome-Scale Constraint-Based Metabolic Models.

MechAInistic: An LLM-guided Multi-Agent System for Reasoning over Genome-Scale Constraint-Based Metabolic Models.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated IDH1 acute myeloid leukemia: insights from a case report.

Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated IDH1 acute myeloid leukemia: insights from a case report.

Journal: Postgraduate medicine

Published: May 11, 2026

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

Journal: Leukemia research

Published: April 14, 2026

Pharmacologic progress in higher-risk MDS: an uphill battle.

Pharmacologic progress in higher-risk MDS: an uphill battle.

Journal: Expert opinion on pharmacotherapy

Published: March 10, 2026

Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency.

Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency.

Journal: Journal of medicinal chemistry

Published: March 06, 2026

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.

Journal: Frontiers in medicine

Published: February 26, 2026

Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia.

Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia.

Journal: Australian prescriber

Published: February 25, 2026

Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy.

Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 23, 2026

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Journal: Journal of personalized medicine

Published: February 16, 2026

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis.

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma.

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Showing 1-12 of 379

Last Updated: 06/30/2026